Bio-Gene Technology Ltd. (BGT) AI Stock Analysis

• Market Cap: AU$10.68M
• Dividend Yield: N/A
• Average Volume (3M): 988.87K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.48
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 305,061,100
• 10 Day Avg. Volume: 246,330
• 30 Day Avg. Volume: 988,871
• PEG Ratio: 0.21
• Price to Book (P/B): 2.08
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: AU$0.04 ▲(80.00% Upside)
• Action: Reiterated Date: 01/20/26
• Date: Action: Reiterated 01/20/26

The score is held down primarily by weak financial performance—near-zero revenue, ongoing losses, and sustained cash burn—despite low leverage. Technicals show a strong recent move (price above major moving averages and positive MACD), but overbought signals (high RSI and very elevated Stoch) temper the upside. Valuation support is limited because the company is loss-making (negative P/E) and has no stated dividend yield.

Positive Factors

Low leverage / clean balance sheet

A very low debt load reduces refinancing and interest risk, preserving financial optionality for a development-stage biotech. This durable strength means management can access capital or prioritize R&D without heavy fixed financing costs, supporting longer-term project flexibility.

Improving free cash flow trend

An improvement in free cash flow, even if modest, signals operational progress or cost control that can reduce near-term funding pressure. Sustained improvement would enhance runway and lower dependence on dilutive financing, improving long-term strategic options for development.

Controlled loss trajectory

Stable (non-accelerating) losses indicate management has some control over operating expenditures. In a cash-burning biotech, predictable and contained losses improve planning, extend runway, and make future funding needs and milestone execution more manageable over the medium term.

Negative Factors

Near-zero revenue

A collapse to near-zero revenue undermines commercial viability and means the business lacks recurring cash generation. Over 2–6 months this structurally increases reliance on external funding, limits reinvestment capacity, and raises execution risk for product development and commercialization.

Persistent negative operating and free cash flow

Sustained negative operating and free cash flow indicates the company consumes capital to operate and develop assets. This structural cash burn shortens runway absent financing, increases dilution risk, and constrains the ability to scale or invest, pressuring long-term sustainability.

Shrinking equity / net worth

Material declines in equity reflect accumulated losses that weaken the balance sheet and reduce borrowing/strategic flexibility. Over time this erodes creditor and investor confidence, limits collateral for financing, and raises the cost and difficulty of funding future development.

Bio-Gene Technology Ltd. Business Overview & Revenue Model

Company Description

Bio-Gene Technology Limited, an agtech development company, engages in developing and commercializing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has research collaborations with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.

How the Company Makes Money

Bio-Gene Technology Ltd. generates revenue through the commercialization of its proprietary pest control technologies. The company's primary revenue streams include licensing agreements with agricultural and chemical companies that incorporate BGT's technology into their own product lines. Additionally, BGT engages in strategic partnerships to co-develop and distribute its products, allowing for shared revenue and expanded market reach. The company may also receive funding through grants and research collaborations aimed at advancing its technology and expanding its application areas. Sales of its own branded products, if applicable, would also contribute to its earnings.

Bio-Gene Technology Ltd. Financial Statement Overview

Summary

Financials are very weak: revenue has fallen to effectively zero, profitability remains deeply negative with persistent losses, and operating/free cash flow are significantly negative (ongoing cash burn). The main offset is a relatively clean balance sheet with minimal debt, but equity has been shrinking due to continued losses.

Income Statement

The income statement remains very weak: revenue has effectively collapsed to zero in 2025 (annual) after several years of small, volatile sales, and profitability is deeply negative with multi-million losses each year. Margins are consistently negative (gross profit also negative in most years), indicating the business is not yet operating at a commercially sustainable scale. A modest positive is that losses have not accelerated dramatically versus the prior year, but overall the trajectory is unfavorable due to declining revenue and persistent operating losses.

Balance Sheet

The balance sheet is a relative bright spot: debt is minimal (near-zero most years; ~A$51k in 2025) and leverage is low, which reduces financial risk. However, equity has fallen materially from 2022 to 2025, reflecting ongoing losses and capital consumption, and returns on equity are sharply negative. Overall, the company appears lightly levered but shrinking in net worth due to continued losses.

Cash Flow

Cash flow quality is weak: operating cash flow and free cash flow are significantly negative in most years (and strongly negative again in 2023–2025), consistent with a cash-burning development-stage profile. There was one year of positive operating cash flow in 2022, but it was not sustained. A partial positive is that free cash flow improved in 2025 versus 2024, yet the business still requires ongoing funding to cover operating outflows.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	0.00	0.00	18.32K	149.23K	445.73K	62.61K
Gross Profit	-47.16K	-245.78K	-301.45K	-164.04K	178.59K	-110.59K
EBITDA	-3.32M	-2.58M	-2.97M	-3.14M	-2.92M	-2.85M
Net Income	-1.96M	-2.58M	-2.41M	-3.10M	-2.91M	-2.40M
Balance Sheet
Total Assets	1.47M	2.15M	3.16M	3.84M	7.30M	5.00M
Cash, Cash Equivalents and Short-Term Investments	1.08M	1.14M	2.21M	2.99M	6.34M	3.93M
Total Debt	0.00	51.21K	0.00	0.00	0.00	0.00
Total Liabilities	307.71K	522.98K	368.45K	613.88K	1.03M	754.57K
Stockholders Equity	1.17M	1.63M	2.79M	3.22M	6.27M	4.25M
Cash Flow
Free Cash Flow	-1.78M	-2.54M	-2.76M	-3.28M	36.67K	-1.83M
Operating Cash Flow	-1.78M	-2.54M	-2.75M	-3.28M	43.52K	-1.83M
Investing Cash Flow	0.00	0.00	-5.70K	0.00	-6.84K	-3.03K
Financing Cash Flow	2.36M	1.47M	1.98M	-75.00K	4.41M	239.88K

Bio-Gene Technology Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BGT, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 84.49 is Negative, neither overbought nor oversold. The STOCH value of 97.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BGT.

Bio-Gene Technology Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IXC	48 Neutral	AU$9.39M	-3.15	-8.72%	―	―	71.10%
CMB	48 Neutral	AU$11.25M	-0.46	-166.70%	―	―	―
BGT	46 Neutral	AU$10.68M	-1.25	―	―	―	―
HXL	40 Underperform	AU$2.17M	-4.31	-28.49%	―	―	46.43%
ZLD	39 Underperform	AU$5.95M	-1.39	―	―	-99.31%	90.20%
1AD	37 Underperform	AU$12.75M	-0.48	-628.72%	―	―	31.87%

Bio-Gene Technology Ltd. Corporate Events

Bio-Gene Targets 2027 APVMA Filing as Flavocide Toxicology Program Advances

Bio-Gene Technology has reported solid progress in the regulatory development of its novel insecticidal active constituent, Flavocide, with a series of toxicology and metabolism studies advancing according to plan. Early toxicology data have been sufficient to move into major reproductive and neurotoxicity studies, which are expected to deliver results in mid and late 2026.

The company is targeting March 2027 for its first submission to the Australian Pesticides & Veterinary Medicines Authority to register Flavocide as a new active constituent, initially to support professional and domestic insecticide products rather than food-related uses. Data are being generated to OECD standards to facilitate subsequent filings in the U.S. and other key markets, marking a critical milestone in commercialising Bio-Gene’s technology and potentially strengthening its competitive position in the insecticide industry.

The most recent analyst rating on (AU:BGT) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Bio-Gene Technology Ltd. stock, see the AU:BGT Stock Forecast page.

Bio-Gene Advances Bio-Insecticide Pipeline with New Approvals, Grants and Capital Raise

Bio-Gene reported its financial and operational progress for the half year to 31 December 2025, highlighting steady advancement of its bio-insecticide portfolio. The company completed its 14th Qcide harvest, advanced biomass pre-treatment and extraction optimisation, and continued investing with partners in refining Flavocide formulations for key applications.

Operationally, Qcide secured listing approval from the U.S. Organic Materials Review Institute as a botanical pesticide under the USDA National Organic Program, while Purdue University researchers presented positive Flavocide efficacy data against tick-borne disease vectors. Bio-Gene also identified additional product applications and faster-path Qcide product opportunities, won A$3 million in U.S. Department of Defense funding for two development programs, undertook strategic partner outreach across Asia, completed an annual strategic review, and strengthened its balance sheet with A$2.46 million raised via a placement and share purchase plan.

The most recent analyst rating on (AU:BGT) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Bio-Gene Technology Ltd. stock, see the AU:BGT Stock Forecast page.

Bio-Gene Advances Pivotal Flavocide Toxicity Study Toward Regulatory Approval

Bio-Gene Technology has commenced a pivotal extended one-generation reproductive toxicity study in rats for its novel insecticidal active ingredient, Flavocide, a core requirement for regulatory approval in Australia and other key jurisdictions. The study, conducted under OECD 443 guidelines and Good Laboratory Practice, will generate essential reproductive, developmental and systemic toxicity data to support Flavocide’s registration with the Australian Pesticides & Veterinary Medicines Authority and underpin its broader commercialisation strategy.

A completed dose range-finding phase has established dosing for the main study, whose in-life phase is expected to conclude in July 2026, with preliminary results due in September and final reporting in November 2026. As an internationally recognised and mutually accepted test, the OECD 443 study is expected to strengthen Bio-Gene’s mammalian toxicology dossier, marking a significant milestone that could enhance regulatory confidence, facilitate international submissions and advance the company’s position in the global insecticide market.

The most recent analyst rating on (AU:BGT) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Bio-Gene Technology Ltd. stock, see the AU:BGT Stock Forecast page.

Bio-Gene Names New CFO and Company Secretary to Support Commercialisation Push

Bio-Gene Technology Limited has appointed experienced finance executive Drew Speedy as Chief Financial Officer and Company Secretary, effective 1 February 2026, replacing outgoing CFO and Company Secretary Edmond Tern. With more than two decades in senior finance and governance roles across ASX-listed and private companies and a background in financial reporting, corporate governance, capital raisings, M&A, IPOs and ASX compliance, Speedy will oversee the company’s financial stewardship and act as the primary contact with the ASX, bolstering Bio-Gene’s corporate capabilities as it advances its development and commercialisation strategy for its bio-insecticide portfolio.

The most recent analyst rating on (AU:BGT) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Bio-Gene Technology Ltd. stock, see the AU:BGT Stock Forecast page.

Bio-Gene Builds Momentum as Flavocide and Qcide Move Toward Commercial Stage

Bio-Gene Technology reported strong operational momentum in the December 2025 quarter as it advanced both its Flavocide and Qcide insecticide platforms from foundational R&D into more mature regulatory, formulation and commercial development. The company is prioritising a suite of safety studies and formulation work for Flavocide to support multi-jurisdictional registrations, underpinned by successful pilot-scale manufacturing with Rallis India that provides a clearer pathway to scale-up and future supply agreements. Qcide development continues to benefit from improved plantation yields and biomass processing in Far North Queensland, while its recent approval for listing by the US Organic Materials Review Institute as a botanical pesticide under the USDA National Organic Program strengthens Bio-Gene’s positioning in organic and sustainable agriculture markets and supports additional product formulations. Bio-Gene is also progressing two US Department of Defense-funded Deployed Warfighter Protection programs: a Flavocide-based wearable mosquito protection device that has entered entomological testing with early evidence of efficacy, and a Qcide-based indoor residual spray targeting bed bugs and other pests that is expected to commence following the resolution of administrative delays in the US. Management highlights a refreshed pipeline of eight active product opportunities and expanding international business development, indicating the company is positioned to achieve further technical, regulatory and commercial milestones as demand grows for safer, biologically derived pest control solutions.

The most recent analyst rating on (AU:BGT) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Bio-Gene Technology Ltd. stock, see the AU:BGT Stock Forecast page.

Bio-Gene Advances US Defense-Funded Insecticide Projects

Bio-Gene Technology Ltd. has provided an update on its two projects supported by A$3.0 million in US Department of Defense grants under the Deployed Warfighter Protection program. The Flavocide wearable device project, designed to protect against mosquitoes, is progressing, with initial trials showing promising results. The Qcide indoor spray project, targeting pests like bed bugs and houseflies, is set to commence in 2026 following recent delays. These programs highlight the company’s focus on addressing the rise of insect-borne diseases with innovative, nature-based solutions for both military and civilian use.